---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-023905"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T15:02:10.430004+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MoonLake raises $460M in offering; Phase 2 MIRA trial meets primary endpoint with HiSCR75 at week 12

## Summary
- Priced 9.2M Class A ordinary shares at $50/sh (8M firm + 1.2M option) for $460M gross proceeds.
- Phase 2 MIRA trial (234 patients) met HiSCR75 primary endpoint: 120mg dose had 29 ppt delta to placebo (p=0.0002).
- HiSCR50 delta 38 ppt (p<0.0001); secondary endpoints including HiSCR90, IHS4, pain, quality of life all significant.
- SLK safety consistent with prior IL-17 inhibitor profile; no new signals observed.
- Entered global royalty-bearing license with RCT for Pichia pastoris manufacturing process for SLK.

## SEC filing metadata
- accession: 0001628280-23-023905
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000162828023023905/0001628280-23-023905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000162828023023905/mltx-20230627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-023905
- JSON: https://secwatch.observer/filing/0001628280-23-023905.json
- Plain text: https://secwatch.observer/filing/0001628280-23-023905.txt

## Key facts
- Material Agreements
  MoonLake Immunotherapeutics entered into Underwriting Agreement with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters valued at $460 million (effective 2023-06-27).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters
  - Value: $460 million
  - Effective: 2023-06-27
  source text: On June 27, 2023, MoonLake Immunotherapeutics (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 8,000,000 Class A ordinary shares, par value per share $0.0001 (the “Firm Shares”), at a public offering price of $50.00 per share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000162828023023905/0001628280-23-023905-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.